Loading...
•
Mar 31, 2025
Selecta Biosciences Q1 2025 Earnings Report
Selecta Biosciences reported Q1 2025 earnings with modest collaboration and grant revenue and a continued net loss as clinical development spending remained elevated.
Key Takeaways
Cartesian Therapeutics generated $1047000 in revenue in Q1 2025 from collaboration and grant funding while reporting a net loss of $17700000 as the company continued investing in the clinical development of Descartes-08 and other autoimmune programs.
Revenue totaled $1047000 from collaboration and grant funding sources.
Net loss was $17700000 with EPS of -0.68.
Operating loss reached $18200000 driven by R&D and administrative spending.
Cash, cash equivalents and restricted cash totaled $187200000 supporting ongoing clinical trials.
Revenue by Segment
Forward Guidance
Cartesian Therapeutics expects existing capital to support continued clinical development of Descartes-08, including the Phase 3 AURORA trial in myasthenia gravis and expansion into additional autoimmune disease indications.
Positive Outlook
- Phase 3 AURORA trial progressing in myasthenia gravis.
- Descartes-08 showed durable responses in prior clinical studies.
- Pipeline expansion planned across multiple autoimmune indications.
- Cash resources support ongoing clinical development programs.
- Additional clinical milestones expected throughout 2025.
Challenges Ahead
- Company remains pre-commercial with limited revenue generation.
- Operating losses continue due to heavy R&D investment.
- Future results depend heavily on clinical trial outcomes.
- Regulatory approval timelines remain uncertain.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...